Objective: The objective of the study was to determine the rate of early onset group B streptococcus (EOGBS) infection in Utah and identify potential areas of failure in EOGBS prevention.
Introduction
During the 1970s, invasive group B streptococcus (GBS) disease emerged as the leading cause of neonatal morbidity and mortality in the United States. [1] [2] [3] [4] Multiple clinical trials demonstrated that the administration of intrapartum antibiotic prophylaxis (IAP) to mothers colonized with GBS was an effective means of preventing GBS infection that occurred before 7 days of age, that is, early onset (EOGBS) disease. 5 As a result, the Centers for Disease Control and Prevention (CDC) published guidelines recommending risk-based screening and prophylaxis of GBS carriers in 1996. These guidelines were revised in 2002 to recommend routine GBS screening of all pregnant women between 35 and 37 weeks' gestation and the administration of IAP during labor to all who test positive. 6, 7 The CDC, in conjunction with health departments and universities in selected counties of 10 states, tracks GBS infection rates by the Active Bacterial Core surveillance of the Emerging Infections Program network. 8 In 1990, there were 1.8 cases per 1000 live births of EOGBS disease nationwide. 9 With increasing use of IAP the national incidence of EOGBS had decreased to 0.34 cases per 1000 live births by 2004. 10 However, the reduction in EOGBS disease has not been uniform across the US. Geographic variations in EOGBS rates have been noted, ranging from 0.53 cases per 1000 live births in Tennessee to 0.14 in Oregon. 11 There are also variations in EOGBS rates among racial groups. The incidence among black infants increased 70% during the years 2003-2005, whereas rates decreased among white infants. 12 In 2005, among black infants in the United States, the rate of EOGBS was 0.84 per 1000 live births compared with 0.24 per 1000 deliveries in white infants. 13 Utah, with a predominantly white population, would, therefore, be expected to have relatively low rates of EOGBS disease.
Although regional variations in EOGBS case rates may be partially explained by differences in racial demographics, they may also be attributable to variations in the implementation of the CDC guidelines for prevention of EOGBS disease. Because Utah has modest racial diversity, its rates of EOGBS disease may be more reflective of how well the 2002 CDC guidelines have been implemented. The objectives of our study were to examine the rates and clinical presentation of EOGBS disease in Utah using information from Intermountain Healthcare (IH), the largest health system in Utah, and to determine if there were failures in the process of care designed to prevent EOGBS infection. We hypothesized that cases of EOGBS would be associated with specific failures of implementation of the CDC guidelines.
Methods

Human subjects protection
The Institutional Review Boards of the University of Utah and IH reviewed and approved the study. Consent was waived.
Setting
The study was conducted in the IH system. IH is a large, vertically integrated medical system based in Salt Lake City, UT. It is the largest nonprofit health care system in the Intermountain West and operates 20 hospitals in the region, including 19 in Utah. Of all, 18 IH hospitals provide delivery and newborn services. Births within the IH system represent approximately 60% of all births in Utah. 14 All IH facilities share a computerized medical record, and data are archived in the Enterprise Data Warehouse.
IH has policies and protocols in place that are compliant with 2002 CDC guidelines for the prevention of EOGBS. 6 Within the IH system, rectovaginal swabs for GBS screening are collected between 35 and 37 gestational weeks using BBL culture swabs (Becton, Dickinson and Company, Sparks, MD, USA) and Amies transport medium. IH Laboratory Services process all GBS screening cultures as follows. Within 48 h of collection, specimens are placed in a selective broth medium (LIM). Then, in compliance with CDC guidelines, the broth is subcultured on sheep blood agar plates. Some women who deliver at IH facilities receive prenatal care and GBS screening in non-IH facilities.
Identification of EOGBS cases in the intermountain system
The computerized microbiology records of IH were queried for all cases of culture-confirmed EOGBS infection between 1 January 2002 and 31 May 2006. We defined cases of EOGBS as infants <7 days of age with a culture of either blood, cerebrospinal fluid or both that was positive for GBS or infants with chest X-ray and clinical findings consistent with pneumonia and a tracheal aspirate positive for GBS.
Data collected
After identifying the infants who met the above case definition, we reviewed the infant and maternal medical records. Abstracted data included demographic information, maternal and neonatal factors known to be associated with EOGBS, microbiological results for mothers and infants, and the elements of the EOGBS prevention strategy. These included whether the mother had received GBS screening, the results of the screening, implementation of IAP if indicated and whether the IAP conformed to CDC recommendations.
Statistical analysis
Annual and total rates of EOGBS infection per 1000 live births in all IH facilities combined and in individual IH facilities were calculated for the period of 1 January 2002 to 31 May 2006. Categorical variables were analyzed with w 2 -test or Fisher's exact test as appropriate. To assess whether the annual IH EOCGB infection rates were stable across the 5 years, we first fit random effects Poisson regression models, to account for a facility effect. The intraclass correlation was 0 to 6 decimals and not significant by a likelihood ratio test, indicating no need to account for facility. This approach was replaced, then, by an ordinary Poisson regression model, using year as a continuous predictor variable to test for linear trend. Year was included in the model both as a continuous predictor to assess linear trend and, in a separate model, as indicator variables to assess a nonlinear trend. In another model, all 5-year indicators were included, with the intercept suppressed, and then rates between the 5 years compared by using a post-estimation test, which simultaneously compared the five regression coefficients. All statistical comparisons were performed using Stata 10 statistical software (StataCorp, College Statation, TX, USA).
We examined the infant and maternal medical records of each case of EOGBS for evidence to suggest a potential breakdown in one or more of the elements of the prevention process. The types of EOGBS infection are shown in Table 1 . Bacteremia, with or without an additional focus was the most common manifestation, occurring in 51 of the 54 infants (94%). Meningitis was diagnosed in 5 of the 54. Three infants met the definition of EOGBS pneumonia. All 54 newborns received appropriate antibiotic treatment for EOGBS infection. 6 
Results
Cases of EOGBS in the IH system
Demographic characteristics of EOGBS cases
The demographic characteristics of the 54 infants with EOGBS are shown in Table 1 . Of all, 42 (78%) were non-Hispanic white infants; 42 (78%) were born at X37 weeks of gestation.
Clinical features and outcomes of infants with EOGBS infection
Clinical signs of infection were present in 48 of the 54 infants (89%) within the first 24 h following birth. Of the remaining cases, four (7%) were diagnosed by 48 h and two (4%) by 72 h. No infant with EOGBS was diagnosed more than 72 h following delivery. There was no consistent relationship between onset of symptoms and whether the mother received IAP.
The clinical signs of infection are shown in Table 2 . Respiratory distress was the most common presentation of EOGBS infection, occurring in 34 of the 54 infants (63%). Three asymptomatic babies (6%) were diagnosed and treated as a result of a positive blood culture that had been obtained because of the presence of maternal risk factors. These included maternal fever (n ¼ 1), known maternal GBS colonization in a mother who had not received IAP (n ¼ 1) and preterm delivery (n ¼ 1).
Of the 54 infants, 3 died, resulting in a case mortality of 5.6%. All of the deaths occurred in preterm newborns. The first was a twin born by caesarian section at 23 3/7 weeks to a mother who was given penicillin just before surgery. A GBS culture, obtained during labor, was positive. The infant's twin survived. The second preterm infant was born at 34 6/7 weeks. We were unable to determine if intrapartum antibiotics were administered. The third death attributable to GBS occurred in an infant born at 30 3/7 weeks to a mother with prolonged rupture of membranes. She was not given intrapartum antibiotics. A culture obtained during labor was positive for GBS. All of the preterm infants who died of GBS infection developed respiratory distress within 24 h of birth.
Potential failure points in the EOGBS prevention care process Preterm birth. Of the 54 infants, 12 were born prematurely (22%), either before (<35 weeks, n ¼ 7) or during (35-37 weeks, n ¼ 5) the screening window (Figure 1 ). Of these, six had GBS cultures performed during labor; the results of these cultures were not available until after the baby had been delivered. Of the 12 preterm infants, 6 were born to women who had no GBS cultures.
Failure to screen term deliveries. Of the remaining 42 women who delivered after the screening window, 39 had been screened for GBS (93%), and 3 (7%) had not. Of the unscreened mothers, two delivered at home and had received little prenatal care. We could not identify a reason why the remaining woman had not been screened.
Inadequate IAP administration to women with positive GBS screens. Of the 39 women whose babies were diagnosed with EOGBS and who had been screened prenatally, 8 (21%) had a positive result. Of these women, 7/8 received antibiotics during labor; the one who did not receive IAP delivered at home. One GBSpositive woman received ampicillin more than 4 h before delivery. Her infant developed symptoms of EOGBS disease within 24 h of birth. Two women received clindamycin. CDC guidelines for IAP advise that if clindamycin is used, susceptibility testing should be performed on the rectovaginal cultures; this was not performed in these two cases. Of note, susceptibilities were performed on the GBS-positive blood cultures of these two infants: one demonstrated clindamycin resistance, whereas the other was susceptible. In the four remaining women who were treated, the interval between IAP administration and delivery of the infant was less than 4 h.
Negative GBS screening results. Of the 45 women who delivered infants with EOGBS and who had GBS cultures obtained prenatally or during labor, 35 (78%) had a negative result. There was no statistical difference between timing of GBS culture and negative results. Of the 39, 31 (79%) cultures obtained during routine prenatal care were negative compared with 4 of the 6 (67%) cultures obtained during labor and delivery (P ¼ 0.60).
Of the 39 women who had routine prenatal GBS cultures obtained, 17 received prenatal care at non-IH facilities, and 22 were cared for within the IH system. The likelihood of a woman having a negative GBS culture and subsequently delivering a baby who developed EOGBS did not differ between these two groups: 18 of 22 women (82%) receiving prenatal care within IH had negative GBS screening cultures compared to 13 of 17 (76%) receiving prenatal care elsewhere (P ¼ 0.71). 
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Discussion
We found an EOGBS infection rate of 0.42 per 1000 live births in the study population, a rate that is 75% higher than the national average of 0.24 per 1000 live births for Caucasian deliveries. We also found that the majority of the cases appeared to be associated with failure of microbiological screening despite adherence to the CDC recommendations. These higher than expected infection rates remained constant over the 4-year study period, even as the CDC's 2002 guidelines for universal GBS screening and targeted intrapartum prophylaxis became increasingly adopted and practiced in the IH system. 15 The clinical findings in the cases of EOGBS described in our study were similar to those classically described. 16 Most occurred in term infants, presented with respiratory symptoms within 24 h of birth, and were associated with bacteremia with or without pneumonia. 17 Although term infants accounted for 42 of the 54 cases of EOGBS, all of the deaths occurred in preterm infants. This difference in mortality is consistent with other studies. 18, 19 The strategy for prevention of EOGBS contains two essential elements. First, all pregnant women are to be screened for the presence of GBS by the collection of rectovaginal swabs between 35 and 37 weeks' gestation, with the swabs then being processed according to CDC protocols. Second, women who are GBS positive are to receive appropriate IAP. We found that there were apparent breakdowns in both of these elements that may have led to the some of the cases of EOGBS and that some of these elements were, at least potentially, modifiable.
A total of 12 infants in this study were born prematurely, and therefore did not have GBS screening results available at the time of maternal presentation to labor and delivery. Prematurity is not a modifiable aspect of the current EOGBS prevention strategy, though it is an indication for antibiotic prophylaxis.
Failure to perform GBS screening in term pregnancies was not a significant problem. Of the women delivering term infants with EOGBS, 93% had prenatal screening for GBS. Two of the three women who were not screened were women who chose alternatives to traditional health care, delivered at home, and did not have prenatal care at a medical facility. If these two women are excluded from the analysis, then 98% of women who received prenatal care in a medical setting and delivered an infant with EOGBS were screened for GBS carriage. This high rate clearly demonstrates the acceptance of GBS screening by obstetrical providers in Utah.
Failure to administer appropriate IAP to mothers who were known to be GBS positive when they presented in labor was associated with seven cases of EOGBS disease. In one case, an infant was delivered at home, thereby eliminating IAP as recommended by CDC guidelines. In four cases, the interval between IAP administration and delivery was less than 4 h; the timing of antibiotic administration in relation to delivery of the infant is difficult to control and, in some instances, it may not be possible to administer antibiotics in the time frame suggested by CDC guidelines. Two of the GBS-positive women received clindamycin with no susceptibility testing, a necessary step in determining whether clindamycin will be adequate for prevention of EOGBS. Within the IH system in 2007, GBS isolates that underwent susceptibility testing had a 20% rate of clindamycin resistance. These findings underscore the importance of routine susceptibility testing when processing maternal GBS screening cultures in penicillin-allergic women. Although providers practicing in IH facilities have protocols in place to promote adherence to the CDC guidelines, it is possible that some of the failures to initiate timely and appropriate prophylaxis could be attributed to lack of adherence to the CDC prophylaxis recommendations. In addition, the fact that 31 term infants with negative maternal GBS screens developed EOGBS disease despite adherence to recommended screening and treatment guidelines should serve as a reminder to newborn care providers that the current strategy is not perfect. Finally, the most common area of apparent breakdown in EOGBS prevention was the high rate of negative GBS screening cultures. Of the 39 women who had prenatal screening for GBS and delivered infants with EOGBS, 79% had a screening test performed at the appropriate time that was negative. A similar high rate of negative screening tests was reported by Puopolo et al. 20 who found that 82% of mothers who gave birth to term infants with EOGBS disease had negative GBS screens. There are several possible explanations for these negative screens. Some of the screening specimens may have been collected, transported or processed inappropriately. Numerous clinicians provided prenatal care to these women, and it is possible that some of them may have used improper technique when collecting the specimens. Although IH microbiological laboratories follow the guidelines for GBS culture processing detailed by the CDC, some of the screening cultures were processed at non-IH facilities that may not have followed the CDC guidelines. There was, however, no difference in the proportion of negative results in women whose babies developed EOGBS, and whose GBS screening had been performed outside the IH system, compared with those in whom it was performed in the IH system.
Negative prenatal GBS cultures could be due to maternal factors that affect the sensitivity of culture. Several maternal factors are known to affect GBS culture results, even when specimens are properly obtained and processed. For example, use of antibiotics and various intravaginal preparations are known to cause falsenegative GBS screening cultures. 21 Likewise, GBS maternal colonization may have occurred late in pregnancy, after the prenatal screening test was performed. 22, 23 However, we found that women undergoing GBS testing at the time of labor and delivery were just as likely to have false-negative GBS cultures as those undergoing prenatal screening between 35 and 37 weeks' gestation. This suggests that the cause of negative screening cultures is more likely due to problems associated with GBS culture collection or processing than the late gestational acquisition of GBS.
Our study suggests that current techniques for screening too often produce negative results in a substantial number of women whose babies develop EOGBS. A negative test may falsely reassure providers as they consider their treatment of mothers and infants. In addition, some infants will inevitably be delivered before the recommended screening time, and some women may acquire GBS after having been screened. Ascertainment of maternal GBS status during labor, using sensitive and rapid molecular techniques has the potential to overcome these problems. Rapid polymerase chain reaction (PCR) assays, using either conventional or fluorogenic techniques, have a sensitivity of 97% and a specificity of 100% compared with traditional culture results. 24 Turnaround time for these tests ranges from 30 to 45 min for the newer fluorogenic PCR assay to 100 min for conventional PCR assays. 24 Numerous commercial PCR assays are currently available with sensitivities and specificities approaching 100%. 25 The FDA has approved the use of a real-time PCR assay for detection of GBS DNA from combined vaginal and rectal swab specimens. 26 A cost-effectiveness analysis performed by Haberland et al. 27 found that use of rapid PCR to detect maternal GBS colonization at the time of labor saved money and resulted in decreased morbidity and mortality compared with risk-based approaches to neonatal GBS disease prevention. IH is moving toward implementation of this technology in all of its delivery facilities.
This study has several limitations: (1) we used a rigorous definition of EOGBS disease, that is, a positive culture. This may have resulted in an underestimate of the number of actual clinical cases. (2) The rates of EOGBS disease reflect experience in the IH system. Though it accounts for approximately 60% of births within Utah, IH may not accurately represent the experience of the rest of Utah's population. (3) Moreover, EOGBS disease in Utah may differ from the rest of the country due to genetic, environmental or geographic differences unique to Utah, and the reasons for continuing cases that we found may also differ. Previous studies have examined EOGBS disease in urban, racially diverse, or otherwise higher risk populations. This study is the first to report increased EOGBS cases in a predominantly low-risk setting with near universal prenatal screening in eligible patients, thus allowing the processes of prevention to be more closely examined.
Conclusion
The implementation of universal maternal GBS screening and IAP of GBS carriers has led to a significant decrease in GBS-related neonatal morbidity and mortality in the United States, but EOGBS disease continues to occur, even in low-risk populations. Methods that facilitate appropriate use of IAP, such as standard susceptibility testing for clindamycin and process improvement that assures timely administration of IAP may be important in reducing the frequency of EOGBS disease.
Improving the accuracy of maternal GBS screening procedures appears to be the best way to reduce EOGBS disease. Further research should be undertaken to determine if rapid PCR testing at the time a woman presents in labor improves outcomes for mothers with GBS colonization and their infants.
